FDA, LabCorp, and Charles River Laboratories Partner on Medicine Abuse Science
What happened
LabCorp announced a collaboration with the U.S. Food and Drug Administration and Charles River Laboratories on October 22, 2026. The research aims to advance the science used to evaluate a medicine's abuse potential. The partnership will use a harmonized behavioral economics methodology to quantify and rank this risk, supporting safer drug development and informed regulatory decisions.
From prnewswire.com
Why it matters
The collaboration seeks to improve how abuse-related risks are evaluated throughout the drug development and regulatory review process. By advancing the science of abuse potential, the partnership could influence regulatory decisions regarding new medicines.
From prnewswire.com
Who's involved
- FDAU.S. Food and Drug Administration, which is partnering to evaluate medicine abuse potential.
- LabCorpLabCorp, a global laboratory services provider contributing experience in regulatory abuse potential studies.
- Charles River LaboratoriesCharles River Laboratories, a major biomedical company collaborating on the abuse potential evaluation.
Keep exploring
The entities involved
- FDA
-
LabCorp
clinical laboratory company
-
Charles River Laboratories
major US biomedical company
Nothing else this week.
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA warnings are influencing local regulatory action as a local council addresses substance health risks.
- LabCorp is involved in FDA-approved drugs. Intuitive Surgical's systems were FDA-cleared. Masimo develops noninvasive patient monitoring technologies.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- AMA urges FDA to maintain standards as federal government implements marijuana rescheduling order amid GAO findings of regulatory deficiencies.